Sprint and T-Mobile propose a major merger in order to better compete with AT&T and Verizon.

Joseph Corr

2018-05-03 07:34:00 Thu ET

Sprint and T-Mobile propose a major merger in order to better compete with AT&T and Verizon. This mega merger is worth $26.5 billion and involves an all-stock deal that exchanges 9.75 Sprint shares for each T-Mobile share. The bipartite company retains the T-Mobile name, keeps its CEO John Legere, and encompasses about 120 million subscribers. This merger carries about $146 billion enterprise valuation with debt in comparison to $313 billion Verizon enterprise value and $334 billion AT&T enterprise valuation. The latter telecom titans invest in substantial fiber-optic, wireless telecom, telephone, can cable television operations.

Joining forces would allow the company to build out a 5G wireless network in direct competition with AT&T and Verizon. This new merger clears the cloudy practices that may harm consumer benefits in the prior M&A attempt back in 2014. T-Mobile and Sprint suggest that times have changed a great deal since 2014 since several companies such as Comcast now enter the mobile business. Moreover, the White House advocates that 5G wireless communication technology is crucial for national economic security reasons. Many stock analysts now consider this mega merger to take place with a 50%+ chance of regulatory approval.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Berkeley professor and economist Barry Eichengreen reconciles the nominal and real interest rates to argue in favor of greater fiscal deficits.

Joseph Corr

2019-05-23 10:33:00 Thursday ET

Berkeley professor and economist Barry Eichengreen reconciles the nominal and real interest rates to argue in favor of greater fiscal deficits.

Berkeley professor and economist Barry Eichengreen reconciles the nominal and real interest rates to argue in favor of greater fiscal deficits. French econo

+See More

Many successful business organizations develop their distinctive capabilities and unique value propositions for strategic reasons.

Jacob Miramar

2020-09-17 12:28:00 Thursday ET

Many successful business organizations develop their distinctive capabilities and unique value propositions for strategic reasons.

Many successful business organizations develop their distinctive capabilities and unique value propositions for strategic reasons. Paul Leinwand and Cesa

+See More

Warren Buffett stock market investment principles

Daphne Basel

2020-02-05 10:28:00 Wednesday ET

Warren Buffett stock market investment principles

Our proprietary AYA fintech finbuzz essay shines light on the modern collection of business insights with executive annotations and personal reflections. Th

+See More

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Olivia London

2017-11-27 07:39:00 Monday ET

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Is it anti-competitive and illegal for passive indexers and mutual funds to place large stock bets in specific industries with high market concentration? Ha

+See More

President Trump applies an increasingly bellicose stance toward the Iranian leader Hassan Rouhani.

Jacob Miramar

2018-08-09 16:36:00 Thursday ET

President Trump applies an increasingly bellicose stance toward the Iranian leader Hassan Rouhani.

President Trump applies an increasingly bellicose stance toward the Iranian leader Hassan Rouhani as he rejects a global agreement to curb Iran's nuclea

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More